Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
Glaukos (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology for treating glaucoma, corneal disorders, and retinal diseases, has announced it will release its fourth quarter and full year 2024 financial results after market close on February 20, 2025.
The company has scheduled a conference call and simultaneous webcast for 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Investors can access the webcast through the company's investor relations website, while those wishing to participate in the conference call can dial 888-210-2212 (U.S.) or 646-960-0390 (International) using Conference ID 7935742.
Glaukos (NYSE: GKOS), un'azienda specializzata in farmaci oftalmici e tecnologie mediche per il trattamento del glaucoma, dei disturbi corneali e delle malattie retiniche, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 dopo la chiusura del mercato il 20 febbraio 2025.
L'azienda ha programmato una conferenza telefonica e una trasmissione web simultanea per le 1:30 p.m. PT (4:30 p.m. ET) dello stesso giorno per discutere i risultati. Gli investitori possono accedere alla trasmissione web tramite il sito web delle relazioni con gli investitori della società, mentre coloro che desiderano partecipare alla conferenza telefonica possono componere il numero 888-210-2212 (USA) o 646-960-0390 (Internazionale) utilizzando l'ID Conferenza 7935742.
Glaukos (NYSE: GKOS), una empresa especializada en productos farmacéuticos oftálmicos y tecnología médica para el tratamiento del glaucoma, trastornos corneales y enfermedades retinianas, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado el 20 de febrero de 2025.
La empresa ha programado una conferencia telefónica y una transmisión web simultánea para las 1:30 p.m. PT (4:30 p.m. ET) el mismo día para discutir los resultados. Los inversores pueden acceder a la transmisión web a través del sitio web de relaciones con inversores de la empresa, mientras que quienes deseen participar en la conferencia telefónica pueden marcar 888-210-2212 (EE.UU.) o 646-960-0390 (Internacional) utilizando la ID de Conferencia 7935742.
글라우코스 (NYSE: GKOS)는 녹내장, 각막 질환 및 망막 질환 치료를 위한 안과 제약 및 의료 기술 전문 회사로, 2025년 2월 20일 시장 종료 후 2024년 4분기 및 연간 재무 결과를 발표할 것이라고 발표했습니다.
회사는 같은 날 오후 1시 30분 PT (오후 4시 30분 ET)에 결과를 논의하기 위해 회의 전화 및 동시에 웹캐스트를 예약했습니다. 투자자들은 회사의 투자자 관계 웹사이트를 통해 웹캐스트에 접근할 수 있으며, 회의 전화에 참여하고자 하는 경우 888-210-2212 (미국) 또는 646-960-0390 (국제)로 전화하여 회의 ID 7935742를 사용하면 됩니다.
Glaukos (NYSE: GKOS), une entreprise spécialisée dans les produits pharmaceutiques ophtalmiques et la technologie médicale pour le traitement du glaucome, des troubles de la cornée et des maladies de la rétine, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année 2024 après la fermeture du marché le 20 février 2025.
L'entreprise a prévu une conférence téléphonique et un webinaire simultané à 13h30 PT (16h30 ET) le même jour pour discuter des résultats. Les investisseurs peuvent accéder au webinaire via le site des relations investisseurs de la société, tandis que ceux souhaitant participer à la conférence téléphonique peuvent composer le 888-210-2212 (États-Unis) ou le 646-960-0390 (International) en utilisant l'ID de conférence 7935742.
Glaukos (NYSE: GKOS), ein Unternehmen, das sich auf ophthalmologische Arzneimittel und Medizintechnologie zur Behandlung von Glaukom, Hornhautproblemen und Netzhauterkrankungen spezialisiert hat, hat angekündigt, dass es seine Finanzberichte für das vierte Quartal und das gesamte Jahr 2024 nach Marktschluss am 20. Februar 2025 veröffentlichen wird.
Das Unternehmen hat für den selben Tag um 13:30 Uhr PT (16:30 Uhr ET) eine Telefonkonferenz und einen gleichzeitigen Webcast geplant, um die Ergebnisse zu erörtern. Investoren können über die Webseite für Investor Relations des Unternehmens auf den Webcast zugreifen, während diejenigen, die an der Telefonkonferenz teilnehmen möchten, die Nummer 888-210-2212 (USA) oder 646-960-0390 (International) anrufen und die Konferenz-ID 7935742 verwenden können.
- None.
- None.
Conference Call and Webcast Scheduled for 1:30 p.m. PT
A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250123829865/en/
Chris Lewis
Vice President, Investor Relations and Corporate Affairs
(949) 481-0510
clewis@glaukos.com
Source: Glaukos Corporation
FAQ
When will Glaukos (GKOS) release Q4 and full year 2024 earnings?
How can investors join the Glaukos (GKOS) Q4 2024 earnings call?
What time is the Glaukos (GKOS) Q4 2024 earnings call?
Will there be a replay available for Glaukos (GKOS) Q4 2024 earnings call?
